<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473443</url>
  </required_header>
  <id_info>
    <org_study_id>PRECISE TAVI</org_study_id>
    <nct_id>NCT04473443</nct_id>
  </id_info>
  <brief_title>Addition of Computer Simulations to Minimize Adverse Events After Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>PRECISE TAVI</acronym>
  <official_title>Addition of Computer Simulations to the Pre-procedural Planning to Minimize Adverse Events After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>feops</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess the influence of FEops HEARTguide on overall device success in
      TAVI patients with challenging anatomies (Cohort A) or in transcatheter heart valve (THV)
      platform selection (Cohort B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      rationale:Transcatheter aortic valve implantation (TAVI) is increasingly used to treat
      patients with severe aortic stenosis. However, by extending the indication for TAVI,
      simulation may become increasingly important to improve procedure execution, safety and
      efficacy.

      objective: This study aims to assess the influence of FEops HEARTguide on overall device
      success in challenging anatomies (Cohort A) or in transcatheter heart valve (THV) platform
      selection (Cohort B).

      Study design: Prospective, observational multi-center trial with 2 cohorts Study Population:
      Cohort A patients with the following complex anatomy are included: BAV (Sievers 0 or 1) or
      functional bicuspid aortic valves, severely calcified aortic valve and small aortic roots.

      Cohort B consecutive patients eligible for TAVI with Acurate TM and Lotus Edge TM valve

      Study Procedure: Participating sites identifies cases and decide if the patient is eligible
      for cohort A or B. The pre-procedural CT-scan will be uploaded to FEops HEARTguide. Heart
      Team decision 1 is according to the clinical routine, including valve type and size,
      pre-dilatation, post-dilatation, preferred implantation depth and comfort scale level.

      Heart Team decision 2 is after the simulation of FEops HEARTguide for the final
      pre-procedural planning. For Cohort A, FEops HEARTguide will give their information about
      sizing and implantation depth. For Cohort B, FEops HEARTguide will give two simulations, one
      with an Acurate valve and one with a Lotus Edge valve.

      The operator will make the final decision about the valve selection. After the procedure the
      implanted device, size and depth are recorded as standard of care. The follow-up period will
      be 30 days. A new CT-scan is recommended. However, this will not be mandatory for this study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall device success conform the VARC-2 document</measure>
    <time_frame>30 days after TAVI</time_frame>
    <description>Incidence of mortality
incidence of stroke
incidence of major vascular complication
incidence of life-threatening bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of more than trivial PVL</measure>
    <time_frame>30 days after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conduction abnormalities and need for new permanent pacemaker implantation</measure>
    <time_frame>30 days after TAVI</time_frame>
    <description>incidence of new permanent pacemaker implantations
incidence of left bundle branch block
incidence of total AV block</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Bicuspid Cardiac Valve</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Patients with a challenging anatomy, including bicuspid aortic valve, severely calcified aortic valves or small aortic roots</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Consecutive patients eligible for TAVI with Acurate TM and Lotus Edge TM valve</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FEops HEARTguideTM</intervention_name>
    <description>A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This prospective multi-center international Registry of TAVI patients include for Cohort A
        patients with the following complex anatomy: BAV (Sievers 0 or 1) or functional bicuspid
        aortic valves, severely calcified aortic valve and small aortic roots.

        And for Cohort B consecutive patients eligible for TAVI with Acurate TM and Lotus Edge TM
        valve
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohort A:

               1. Patients with a Bicuspid Aortic Valve (Sievers 0 or 1) or functional Bicuspid
                  Aortic Valve

               2. Patients with a severely calcified aortic valve (Agatston score &gt; 3000 for men,
                  and &gt; 1600 for women)

               3. Patients with small anatomy defined by mean aortic annulus diameter &lt; 20mm

          -  Cohort B:

               1. every patient accepted for TAVI and eligible for Acurate TM and Lotus Edge valve
                  TM.

        Exclusion Criteria:

          -  poor CT quality

          -  previous aortic valve replacement

          -  Permanent pacemaker at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas van Mieghem, Md,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas van Mieghem, MD, PhD</last_name>
    <phone>+31107035260</phone>
    <email>n.vanmieghem@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thijmen Hokken, MD</last_name>
    <phone>+31107038896</phone>
    <email>t.hokken@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas van Mieghem, MD, PhD</last_name>
      <phone>+31(0)107035260</phone>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23. doi: 10.1016/j.jtcvs.2012.09.002. Epub 2012 Oct 16. Review.</citation>
    <PMID>23084102</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Nicolas van Mieghem</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

